Case Series of Guillain-Barré Syndrome After the ChAdOx1 NCoV-19 (Oxford-AstraZeneca) Vaccine

Overview

Journal Neurol Clin Pract

Date 2022 Jun 24

PMID 35747886

Authors

Miranda Mengyuan Wan

Angela Lee

Ronak Kapadia

Christopher Hahn

Affiliations

Soon will be listed here.

Abstract

Purpose Of Review: Vaccination has been associated with Guillain-Barre syndrome (GBS). Amid a global vaccination campaign to stop the spread of COVID-19, fears of GBS can contribute to vaccine hesitancy. We describe 3 cases of GBS in Calgary, Canada, presenting within 2 weeks of receiving the ChAdOx1 nCoV-19 (COVISHIELD) Oxford-AstraZeneca vaccination and review the available literature.

Recent Findings: All 3 patients presented to the hospital in Calgary, Alberta, Canada, within a one-month time frame with GBS. Their clinical courses ranged from mild to severe impairment, all requiring immunomodulatory treatment.

Summary: There is currently little evidence to support a causal relationship between vaccination and GBS. Furthermore, there is limited evidence to support recurrent GBS in patients with GBS temporally associated with vaccination. Neurologists should approach discussions with patients regarding GBS after vaccination carefully so as not to misrepresent this relationship and to educate patients that the risk of COVID-19 infection outweighs the small individual risk of a vaccine-associated adverse event.

Citing Articles

Heterotopic ossification Post-Guillain-Barre syndrome in Saudi Arabia: a case report.

Aldhilan M, Alshahrani A Ann Med Surg (Lond). 2024; 86(9):5509-5512.

PMID: 39238987 PMC: 11374238. DOI: 10.1097/MS9.0000000000002312.

Neuromuscular diseases associated with COVID-19 vaccines: a systematic review and pooled analysis of 258 patients.

Tayebi A, Samimisedeh P, Afshar E, Mahmoudnia S, Milan N, Ayati A BMC Neurol. 2023; 23(1):437.

PMID: 38082244 PMC: 10712145. DOI: 10.1186/s12883-023-03486-y.

Guillain-Barré syndrome associated with SARS-CoV-2 vaccination: how is it different? a systematic review and individual participant data meta-analysis.

Reddy Y, Murthy J, Osman S, Jaiswal S, Gattu A, Pidaparthi L Clin Exp Vaccine Res. 2023; 12(2):143-155.

PMID: 37214140 PMC: 10193105. DOI: 10.7774/cevr.2023.12.2.143.

Concurrent facial and trigeminal nerve palsies in a child following COVID-19 vaccination with the Pfizer vaccine.

Moezinia C, Harbinson E, Maweni R BMJ Case Rep. 2023; 16(1).

PMID: 36717162 PMC: 9887692. DOI: 10.1136/bcr-2022-253302.

References

Hadden R, Karch H, Hartung H, Zielasek J, Weissbrich B, Schubert J . Preceding infections, immune factors, and outcome in Guillain-Barré syndrome. Neurology. 2001; 56(6):758-65. DOI: 10.1212/wnl.56.6.758. View

Haber P, DeStefano F, Angulo F, Iskander J, Shadomy S, Weintraub E . Guillain-Barré syndrome following influenza vaccination. JAMA. 2004; 292(20):2478-81. DOI: 10.1001/jama.292.20.2478. View

Jacobs B, Rothbarth P, van der Meche F, Herbrink P, Schmitz P, de Klerk M . The spectrum of antecedent infections in Guillain-Barré syndrome: a case-control study. Neurology. 1998; 51(4):1110-5. DOI: 10.1212/wnl.51.4.1110. View

Lunn M, Cornblath D, Jacobs B, Querol L, van Doorn P, Hughes R . COVID-19 vaccine and Guillain-Barré syndrome: let's not leap to associations. Brain. 2020; 144(2):357-360. PMC: 7799242. DOI: 10.1093/brain/awaa444. View

Kusunoki S, Shiina M, Kanazawa I . Anti-Gal-C antibodies in GBS subsequent to mycoplasma infection: evidence of molecular mimicry. Neurology. 2001; 57(4):736-8. DOI: 10.1212/wnl.57.4.736. View

Bourdette D, Killestein J . Quelling Public Fears About Guillain-Barré Syndrome and COVID-19 Vaccination. Neurology. 2021; 96(22):1021-1022. DOI: 10.1212/WNL.0000000000011882. View

Langmuir A . Guillain-Barré syndrome: the swine influenza virus vaccine incident in the United States of America, 1976-77: preliminary communication. J R Soc Med. 1979; 72(9):660-9. PMC: 1436986. DOI: 10.1177/014107687907200908. View

Pritchard J, Mukherjee R, Hughes R . Risk of relapse of Guillain-Barré syndrome or chronic inflammatory demyelinating polyradiculoneuropathy following immunisation. J Neurol Neurosurg Psychiatry. 2002; 73(3):348-9. PMC: 1738021. DOI: 10.1136/jnnp.73.3.348. View

Sejvar J, Baughman A, Wise M, Morgan O . Population incidence of Guillain-Barré syndrome: a systematic review and meta-analysis. Neuroepidemiology. 2011; 36(2):123-33. PMC: 5703046. DOI: 10.1159/000324710. View

10.

Wakerley B, Yuki N . Infectious and noninfectious triggers in Guillain-Barré syndrome. Expert Rev Clin Immunol. 2013; 9(7):627-39. DOI: 10.1586/1744666X.2013.811119. View

11.

Waheed S, Bayas A, Hindi F, Rizvi Z, Espinosa P . Neurological Complications of COVID-19: Guillain-Barre Syndrome Following Pfizer COVID-19 Vaccine. Cureus. 2021; 13(2):e13426. PMC: 7978140. DOI: 10.7759/cureus.13426. View

12.

Haber P, Sejvar J, Mikaeloff Y, DeStefano F . Vaccines and Guillain-Barré syndrome. Drug Saf. 2009; 32(4):309-23. DOI: 10.2165/00002018-200932040-00005. View

13.

Chen Y, Zhang J, Chu X, Xu Y, Ma F . Vaccines and the risk of Guillain-Barré syndrome. Eur J Epidemiol. 2019; 35(4):363-370. DOI: 10.1007/s10654-019-00596-1. View

14.

Pabbaraju K, Wong A, Douesnard M, Ma R, Gill K, Dieu P . Development and validation of RT-PCR assays for testing for SARS-CoV-2. J Assoc Med Microbiol Infect Dis Can. 2022; 6(1):16-22. PMC: 9612431. DOI: 10.3138/jammi-2020-0026. View

15.

Schonberger L, Bregman D, Sullivan-Bolyai J, Keenlyside R, ZIEGLER D, Retailliau H . Guillain-Barre syndrome following vaccination in the National Influenza Immunization Program, United States, 1976--1977. Am J Epidemiol. 1979; 110(2):105-23. DOI: 10.1093/oxfordjournals.aje.a112795. View

16.

Fenichel G . Neurological complications of immunization. Ann Neurol. 1982; 12(2):119-28. DOI: 10.1002/ana.410120202. View

17.

Yuki N, Susuki K, Koga M, Nishimoto Y, Odaka M, Hirata K . Carbohydrate mimicry between human ganglioside GM1 and Campylobacter jejuni lipooligosaccharide causes Guillain-Barre syndrome. Proc Natl Acad Sci U S A. 2004; 101(31):11404-9. PMC: 509213. DOI: 10.1073/pnas.0402391101. View

18.

Pollard J, Selby G . Relapsing neuropathy due to tetanus toxoid. Report of a case. J Neurol Sci. 1978; 37(1-2):113-25. DOI: 10.1016/0022-510x(78)90232-0. View

19.

Shaw R, Stuart A, Greenland M, Liu X, Nguyen Van-Tam J, Snape M . Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data. Lancet. 2021; 397(10289):2043-2046. PMC: 8115940. DOI: 10.1016/S0140-6736(21)01115-6. View

20.

Kanji J, Zelyas N, MacDonald C, Pabbaraju K, Khan M, Prasad A . False negative rate of COVID-19 PCR testing: a discordant testing analysis. Virol J. 2021; 18(1):13. PMC: 7794619. DOI: 10.1186/s12985-021-01489-0. View